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Protocol
AbstrAct
Introduction Despite clinical guidelines 
recommendations, many relatives of people with psychosis 
or bipolar disorder do not currently receive the support 
they need. Online information and support may offer a 
solution.
Methods and analysis This single-blind, parallel, 
online randomised controlled trial will determine 
clinical and cost-effectiveness of the Relatives 
Education And Coping Toolkit (REACT) (including an 
online resource directory (RD)), compared with RD 
only, for relatives of people with psychosis or bipolar 
disorder. Both groups continue to receive treatment 
as usual. Independent, web-based variable, block, 
individual randomisation will be used across 666 
relatives. Primary outcome is distress at 24 weeks 
(measured by General Health Questionnaire; GHQ-
28) compared between groups using analysis of 
covariance, adjusting for baseline score. Secondary 
clinical outcomes are carer well-being and support. 
Cost-effectiveness analysis will determine cost of a 
significant unit change (three-point reduction) in the 
GHQ-28. Costs include offering and supporting the 
intervention in the REACT arm, relevant healthcare 
care costs including health professional contacts, 
medications prescribed and time off (or ability to) 
work for the relative. Cost utility analysis will be 
calculated as the marginal cost of changes in quality-
adjusted life years, based on EuroQol. We will explore 
relatives’ beliefs, perceived coping and amount of 
REACT toolkit use as possible outcome mediators. We 
have embedded two methodological substudies in the 
protocol to determine the relative effectiveness of a 
low-value (£10) versus higher value (£20) incentive, 
and an unconditional versus conditional incentive, on 
improving follow-up rates.
Ethics and dissemination The trial has ethical approval from 
Lancaster National Research Ethics Service (NRES)Committee 
(15/NW/0732) and is overseen by an independent Data 
Monitoring and Ethics Committee and Trial Steering Committee. 
Protocol version 1.5 was approved on 9 January 2017. All 
updates to protocols are uploaded to the National Institute 
for Health Research (NIHR) Journals Library. A full statistical 
analysis plan is available at https:// figshare. com/ account/ 
home#/ projects/ 19975. Publications will be in peer-reviewed 
journals (open access wherever possible). Requests for access 
to the data at the end of the study will be reviewed and granted 
where appropriate by the Trial Management Group.
Trial registration number ISRCTN72019945, pre-
results. 
Strengths and limitations of this study
 ► Assesses both clinical and cost-effectiveness of an 
intervention to increase access to National Institute 
for Health and Care Excellence-recommended 
support for relatives of people with psychosis or 
bipolar disorder.
 ► Entirely online trial design and embedded 
methodological studies to determine effective 
incentives for data collection.
 ► Peer-supported intervention with trained relative.
 ► No outcomes assessed for the people with psychosis 
or bipolar disorder being supported.
 ► Registration for the trial requires relatives to be 
currently distressed, which may exclude many 
relatives who still need this kind of support.
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InTroducTIon
Background and rationale
Relatives of people with psychosis/bipolar disorder 
(BD) provide a large amount of unpaid care,1 2 but at 
high personal cost in terms of distress and burden,3–5 
and increased use of healthcare services.6 The UK 
Government recognises the need to support relatives 
in a caring role,7 and the National Institute for Health 
and Care Excellence (NICE) recommends all relatives 
are provided with information and support, and offered 
structured family intervention to enhance family coping 
and communication.8 9 However, a recent national audit 
of Early Intervention (EI) teams for psychosis showed 
poor implementation: only 50% of relatives are receiv-
ingreceiving a carer-focused education and support 
programme; only 31% offered structured family interven-
tion and only 12% receiving it.10
Reasons for poor implementation are likely to be multi-
faceted but likely include limited time and resources 
within teams and among relatives. An online intervention 
to provide the necessary information and support to rela-
tives may improve implementation. Online interventions 
are well established for many mental health conditions, 
including depression and anxiety,11 and are being rapidly 
developed for psychosis12 and BD.13 Such interventions 
are particularly suited to delivering standardised informa-
tion and a platform to share ideas through online forums, 
but cannot replace structured family interventions. 
Online support is also being developed for relatives of 
people with other chronic health conditions,14 and may 
be particularly useful for these groups due to the flexi-
bility of use, and empathy and support from being linked 
to other carers.15
We have developed the Relatives Education And Coping 
Toolkit (REACT) to provide high-quality information and 
support in an easy and free-to-access online form to rela-
tives of people with psychosis or BD. If effective, it could 
help National Health Service (NHS) Trusts meet the 
national access and waiting times target for early inter-
vention services to offer carer information and support 
to all.16
Online interventions may be best evaluated using 
online trial methodology to enhance the external 
validity of the trial.17 Advantages of online trial design 
include the potential to reach a greater number and 
range of participants more representative of the popu-
lation likely to use an online intervention, to recruit 
more people over a shorter timeframe, to offer secure 
randomisation and data entry simpler protocols, and 
for a much cheaper trial due to fewer staff required.18 
However, retention rates can be low,18 19 compromising 
internal validity of the trial. Offering incentives can 
improve retention rates,20–23 but there is considerable 
uncertainty as to the level of incentive required and 
whether the incentive should be conditional or uncon-
ditional on completion.
Study aims and objectives
This randomised controlled trial aims to determine 
the clinical and cost-effectiveness of the REACT toolkit 
(which includes an online resource directory (RD)) and 
treatment as usual (TAU), compared with the RD only 
and TAU. This comparator was chosen to test the effect 
of offering REACT as an additional intervention to what 
relatives are currently able to access.
The objectives are to determine the following:
 ► impact of REACT on relatives’ distress
 ► impact of REACT on relatives’ well-being and support
 ► impact of REACT on hypothesised mediators of 
change, including relatives’ beliefs, perceived coping 
and amount of use of REACT
 ► costs associated with delivery and maintenance of 
REACT
 ► incremental cost-effectiveness ratio of REACT
 ► key issues for which relatives seek support.
We have embedded two methodological substudies. 
The objectives are to determine the effect on follow-up 
rates of the following:
 ► a low-value (£10) versus higher value (£20) incentive
 ► an unconditional versus conditional incentive.
The primary hypothesis is that there will be a significant 
difference (p<0.05) between the two arms of the trial in 
the General Health Questionnaire (GHQ-28) scores at 
24-week follow-up.
MeThodS
Trial design
This is a primarily online, two-arm, pragmatic, single-
blind individually randomised controlled superiority 
trial. Participant pathway through the study is shown in 
figure 1.
Public Patient Involvement (PPI) strategy
One of the study investigators and coauthor is a parent 
of someone living with psychosis and was extensively 
involved in the development of REACT, the RD and 
data collection processes. She is part of the supervisory 
team for the REACT supporters. We have a Relatives’ 
Advisory Group (RAG) working primarily online to 
provide detailed feedback on REACT toolkit, online data 
collection process and recruitment strategy. They will be 
involved in analysis, interpretation and dissemination of 
the data. Our Trial Steering Committee (TSC) includes 
people who are relatives supporting someone with a 
mental health problem.
Setting: uK
This study will take place online in the UK. It is hosted by 
one NHS Foundation Trust, and other Trusts and clinical 
commissioning groups are eligible to take part as partic-
ipant identification centres. Recruitment will also take 
place through local and national mental health charities, 
media, social media and Google Ads.
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Participants
Inclusion criteria
 ► Aged 16 or over
 ► Living in the UK
 ► Relative/close friend of someone with psychosis or 
BD
 ► Currently experiencing distress due to their relative 
or close friend (scoring ≥3 on the GHQ-28 item ‘Have 
you recently been feeling nervous and strung up all 
the time’)
 ► Currently help seeking (self-identified)
 ► Access to an internet-enabled computer
 ► Sufficient English fluency to comprehend intervention 
content
 ► Only one relative per service user may participate to 
avoid a clustering effect.
Figure 1 REACT trial flow chart showing participant pathway through the study. GHQ, General Health Questionnaire; REACT, 
Relatives Education And Coping Toolkit; TAU, treatment as usual.
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Exclusion criteria
As there is a parallel implementation study (called 
IMPART) of the same intervention (http://www. hra. nhs. 
uk/ news/ research- summaries/ implementation- of- an- 
online- relatives- toolkit- impart- study), relatives living in 
any of the six areas where it is running will be excluded 
(by postcode).
recruitment
Recruitment is scheduled from April 2016 to October 
2017. We will develop a social media strategy using Twitter, 
Facebook, Google Ads and blogging, and engage with 
local and national news media. We will recruit through 
national carer networks, MIND, Carers Trust, Rethink 
Mental Illness, Carers UK, SANE, Bipolar UK and NHS 
Choices. These organisations will all be listed in the RD in 
our trial. We will work closely with the Clinical Research 
Network to ensure information about the study is made 
widely available for recruitment through NHS Trusts and 
general practitioner (GP) practices. We will monitor the 
success of these strategies by asking all potential partici-
pants at registration (postconsent) to indicate how they 
heard about the trial and explore differences in demo-
graphics for those entering the study via different routes.
Based on previous studies our strategies to improve 
recruitment include a ‘lead-in’ period during which 
people can register interest in the trial during the set-up 
phase and be contacted directly when the trial starts,24 25 
using online recruitment strategies to target those already 
using the internet to seek help,19 and paying partici-
pants.20
Potential participants will be directed to the study 
home page (www. reacttoolkit. co. uk), which provides 
study information. People visiting the site will provide 
the postcode of the person they care for to check they 
live in the UK, and not in one of the implementation 
study (IMPART) areas. Those in an IMPART area will 
be directed to the IMPART study site. Potential partici-
pants are directed to an online participant information 
sheet that details the study. Relatives are then asked to 
complete a short checklist to indicate whether they meet 
the inclusion criteria listed above.
Non-eligible relatives are invited to leave their contact 
details if they would like to be sent content of the REACT 
modules at the end of the study.
Eligible participants complete an online consent form 
and provide a valid email address. A copy of the consent 
form and a link to the registration process is sent by email 
(email validation step).
The registration process requires multiple contact 
details including mobile phone number, and checks 
for overlap with other participant details. A code is sent 
by text message to invite the relative to access the site. 
The data collection system requires email address and 
the registration name from the user. If any of the 7% of 
the UK population without a mobile phone take part, 
or there are any concerns identified through matching 
registration details, we will ask for a landline and verify 
identity using a code delivered by telephone. We will use 
postcodes to check all participants are living in the UK. 
We will request age and gender at baseline and also at 
12-week and 24-week follow-up, as a final identity check. 
Similar strategies have been used successfully in previous 
trials.23 26
Interventions
Participants can access the intervention site (REACT or 
RD) whenever they wish throughout the period of the 
trial (minimum of 24 weeks to last follow-up for final 
participant). They are advised to use the intervention 
according to the level of need. No changes are made to 
current treatment.
Development of REACT
REACT was developed with extensive input from 
clinicians and relatives through focus groups27 and 
the RAG. The content was first made available in 
paper/online pdf form, and feasibility and effective-
ness in reducing relatives’ distress were demonstrated 
in a randomised controlled trial.28 Based on further 
qualitative feedback from participants in the feasibility 
trial, focus groups with relatives exploring their views 
of online interventions and RAG input, the content 
has been updated and expanded to offer a compre-
hensive online recovery focused toolkit for relatives of 
people with psychosis and/or BD. It includes online 
support from trained relatives (REACT supporters) 
via confidential direct messaging, and from other 
relatives through a restricted access forum moderated 
by the REACT supporters. Support offered by peers 
with a shared lived mental health experience is highly 
valued and can be as effective as support from health 
professionals,29 30 but there is no evidence on the effec-
tiveness of relatives’ peer support. A key advantage of 
this design is that relatives of people who refuse to 
engage with services can be supported.
Each of the 12 key modules contains high-quality stan-
dardised written information, videos of clinical experts or 
experts by experience sharing their knowledge and expe-
riences to illustrate key points, and self-reflection tasks to 
ensure content is personalised to the user. All videos of 
relatives telling their real story were retold by actors to 
preserve anonymity of those involved. A summary of each 
module is given in table 1.
A ‘Meet The Team’ page ensures relatives are fully 
informed about who is delivering the content of the site. 
Logos for Lancaster University, Lancashire Care NHS 
Trust, University College London, Liverpool Clinical 
Trials Research Centre (CTRC) and the McPin Foun-
dation are prominently displayed on the login page. 
Mytoolbox offers user a confidential space to save links to 
any information sources they may want to access easily in 
future, including specific content within the toolkit, their 
self-reflection tasks and external web links. A blog page 
offers a flexible space for additional communication with 
site users, which can be edited by the REACT supporters.
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Support is offered through confidential direct 
messaging with trained relatives (REACT supporters) 
and peer support through a moderated online forum.
Currently available national and local resources are 
listed in the RD. Screenshots in Figure 2 show the look 
and feel of the REACT intervention.
The REACT supporters are available on the site 
Monday to Friday, 09:00–16:30, excluding bank holi-
days and university holiday closures. Their key role 
is to provide emotional support and to guide rela-
tives to relevant parts of toolkit and/or other relevant 
resources as appropriate. They are also trained to 
moderate the forum and can hide posts or withdraw 
access in response to inappropriate use. They are 
trained and supervised by a clinical psychologist and 
an expert relative.
Participants receiving REACT are sent reminders to visit 
the website after a week of inactivity. Participants can change 
the frequency of these reminder emails or turn them off.
RD arm
Participants allocated to RD arm log into the same 
website, but are only able to see the ‘Meet The Team’ 
and RD pages. At the end of the study those in RD only 
will be given access to the modules, without forum or 
direct messaging.
outcomes
Figure 3 shows all of the measures and when they are 
completed.
Table 1 REACT information modules
Title Description
What is psychosis? Information about psychosis, what it feels like, possible causes and common 
misconceptions.
What is bipolar disorder? An overview of bipolar disorder, its main features, the different presentations of bipolar 
and how it feels to experience it.
Managing ‘positive’ symptoms An explanation of what is meant by the term ‘positive symptoms’, how these may be 
experienced, how they might appear to relatives and friends and how they can be 
managed.
Managing ‘negative’ symptoms A detailed description of signs that make up ‘negative symptoms’, how these can 
manifest in people and how relatives can spot them. It explores how these might make 
relatives feel and gives suggestions as to how to help the person experiencing these 
symptoms.
Managing mood swings Information on how to help people avoid extreme lows and highs, maintain a stable mood 
and support a relapse prevention/staying well plan. Suggestions are made on how to 
create a low-stress environment in a friendly, non-judgemental way.
Dealing with difficult situations Describes the difficult situations that relatives and friends sometimes encounter, including 
risky, illegal or embarrassing behaviour, and offers ideas on how to manage these.
Managing stress — doing things 
differently
Helps relatives consider what stresses they have in their lives and how to adapt their own 
behaviours to help manage stressful situations.
Managing stress — thinking 
differently
Helps relatives consider how they are thinking about the stresses in their lives, and 
whether there are different perspectives that may help reduce their distress.
Explores the many common thinking traps people fall into, such as ‘jumping to 
conclusions’ or ‘mind reading’, and helps relatives to test their own thoughts.
Understanding mental health 
services
Supports relative through understanding the complexities of mental health service 
provision to ensure they talk to the right people, to get the right information to meet their 
needs.
Treatment options Information on what people with psychosis, bipolar disorder and also their relatives 
should be offered according to the NICE guidelines, including medication, psychological 
interventions and other therapies. Aims to empower relatives through outlining choices 
available.
Dealing with crisis Clear suggestions about what to do in a crisis, where to turn to for help and what a 
relative should expect from services. Creates a very useful personalised ‘what to do in a 
crisis’ plan.
The future and recovery Focuses on supporting recovery, with useful tips on how relatives can help people with 
bipolar disorder/psychosis develop confidence and gain independence, including finding 
a balance between support and enabling independence, looking for positive changes to 
celebrate, accepting new goals and challenges, and focusing on the bigger picture.
NICE, National Institute for Health and Care Excellence; REACT, Relatives Education And Coping Toolkit.
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Primary outcome
The primary outcome is relatives’ distress at 24 weeks 
assessed using GHQ-28 with Likert scoring.1–4 31 GHQ-28 
showed sensitivity to change previously26 28 and has 
shown significant associations with important functional 
outcomes in the general population, including GP visits,32 
absence from work,33 incapacity benefits34 and severe 
adverse health outcomes, including deaths.35
Secondary outcomes
Secondary outcomes include the relatives’ experience of 
caring assessed using the Carers’ Well-Being and Support 
(CWS) measure36 assessed at 24 weeks, and distress (GHQ-
28) and carer experience (CWS) at 12 weeks’ follow-up. 
CWS covers all aspects of carer’s experience of caring for 
someone with a serious mental health problem, including 
relationships, roles, financial concerns, physical/
emotional health, stigma, worries about safety, satisfaction 
with support offered and ease of obtaining information.
Cost-effectiveness
We will determine the cost of a significant unit change 
(defined as three-point reduction) in GHQ-28. Cost utility 
analysis with fully incremental analysis will be calculated 
as the marginal cost of any changes in quality-adjusted 
life years (QALYs), using EuroQol EQ-5D-5L,37 as recom-
mended by NICE.38 The EQ-5D-5L comprises five items 
covering the domains of mobility, self-care, usual activity, 
pain/discomfort and anxiety/depression.
Costs will include the direct costs of offering and 
supporting the intervention in the REACT arm, rele-
vant healthcare care costs including health professional 
contacts, medications prescribed and time off (or ability 
to) work for the relative in both arms. An adapted version 
Figure 2 Screenshots to show look and feel of the Relatives Education And Coping Toolkit website.
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of the Client Service Receipt Inventory (CSRI)39 will be 
used to collect online retrospective information about 
the participant’s use of health and social care services, 
accommodation and living situations, income, employ-
ment and benefits in the preceding 6 months. We will 
include use of other free interventions including rela-
tives support groups and websites, so we can accurately 
describe current treatment. Unpaid informal care by the 
relatives will be measured by asking relatives how many 
hours of care they provide supporting the person with 
mental health problems, and costing these on an hourly 
basis based on national mean age and gender-specific 
wage rates available from the Office for National Statis-
tics.40 Days lost by relatives from work and reduced hours 
while at work due to the caring role will also be recorded 
and costed as part of the CSRI. Wherever possible, unit 
costs for medication and healthcare resources will be 
taken from national sources such as the British National 
Formulary41 and the Personal Social Services Research 
Unit (PSSRU) Costs of Health and Social Care.42
Mediators of change
To test the proposed mediators of change in relatives’ 
outcomes, we will also include Brief Illness Perception 
Questionnaire,43 a 15-item Likert scale assessing beliefs 
about psychosis/BD with an additional single item, to 
assess perceived coping; and Brief COPE,44 a 28-item 
measure widely used to assess coping styles.
We will record all activity on the toolkit for each 
individual to test the relationship between use and effec-
tiveness. Application Programming Interface data from 
the REACT site will be summarised for participants 
randomised to both intervention groups into a small 
number of variables (number of webpage downloads and 
time spent on the site).
In addition to amount of use, we will explore the nature 
of use, including qualitative analysis of forum posts and 
direct messages. We will also explore potential determi-
nants of web use by assessing relatives’ experiences of the 
intervention for the REACT group only at 12-week and 
24-week follow-up.
Figure 3 Measures and timing of completion.
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data collection
Baseline measures including demographic information, 
outcomes and mediators are completed before rando-
misation. Demographic data collected include age, 
gender, ethnicity, marital status, education, employment, 
living arrangements (including dependents), primary 
diagnosis of service user, length of time in caring role, 
number of people caring for, relationship to person(s) 
with mental health problem, whether or not they live 
with the person(s), level and type of contact, whether or 
not they are receiving support from NHS services and 
internet access.
Twelve and 24 weeks after randomisation, all partic-
ipants are sent an email reminder to complete the 
follow-up measures. At 24 weeks, the email content 
will vary depending on whether participants have been 
randomised to either £10 or £20 reward and to the 
reward being conditional (ie, dependent on completion 
of follow-up questionnaires) or unconditional (ie, offered 
with the initial request for follow-up data).
To maximise follow-up at the primary outcome point 
we will:
1. only randomise participants once baseline assessment 
measures are completed
2. include detailed explanations in our recruitment 
materials to explain to participants why data 
completion at follow-up is so important
3. require email, telephone and postal contact details at 
registration so we have multiple methods of contact 
for follow-up
4. send participants up to three automated email 
reminders at 5-day intervals, followed by text, 
telephone and/or postal requests
5. incentivise completion of follow-up measures by 
paying participants shopping voucher(s) at each time 
point.
To increase overall acceptability and participation rates, 
we will inform RD participants that they will be able to 
access toolkit modules after the final follow-up.
Sample size
We aim to recruit 666 relatives of people with psychosis/
BD to accurately test the primary hypothesis that there 
will be a significant difference (p<0.05) between the trial 
arms in GHQ-28 at 24-week follow-up. Our feasibility trial28 
showed a mean difference in GHQ scores between groups 
at 6 months (controlling for baseline) of 6.59 units (SD 
16.6 units) in favour of the REACT arm. To build a degree 
of protection against pilot results proving optimistic, and 
to accommodate adaptations to the design of the study 
and the intervention, we reduce our estimate of the mean 
difference in this trial from 6.59 to 5.0 units. We retain our 
estimate of SD of 16.60 from the feasibility study, consis-
tent with other studies using this measure with relatives in 
EI services45 and somewhat higher than those from other 
mental health or dementia services.46 47 Four hundred 
and sixty-six participants provides 90% power to reject 
the null hypothesis (p<0.05), with effect size of 5.0 units 
assuming 30% dropout by 24 weeks. Although dropout 
was only 17% in our feasibility trial, it is historically higher 
in online trials.19
Internal pilot
Our trial includes a 9-month internal pilot with the 
following criteria:
 ► GO: 100% or above of anticipated recruitment at 9 
months (333+ participants)
 ► AMEND: 80%–100% of anticipated recruitment (267–
333 participants); review and amend recruitment 
strategies
 ► STOP: <80% of target for 9 months (<267 relatives); 
inform funders who will determine whether to stop 
trial.
If the SD of GHQ-28 scores at 24-week follow-up at the 
end of the internal pilot is higher than the estimated 16.6 
units, the sample size will be recalculated and recruit-
ment targets increased accordingly. If SD is lower, sample 
size will remain unchanged. If GHQ-28 retention at 24 
weeks is less than 70%, recruitment target will increase 
to ensure 466 patients will provide sufficient 24-week 
primary outcome data to test the primary hypothesis.
randomisation
Eligible participants will be randomised using a 1:1 ratio 
to ‘REACT (including RD)+TAU’ versus ‘RD+TAU’ by 
the CTRC. We will use web-based variable block randomi-
sation in which the unit of randomisation is the relative. 
We will explore the effect of sociodemographic and 
caring-related variables; however, without convincing 
evidence these will have an effect, we have not stratified 
randomisation.
A second independent randomisation is carried out at 
CTRC at 24-week follow-up using a randomised factorial 
design using the same individual block randomisation, 
with participants randomised to £10 or £20 reward (shop-
ping voucher) and to the reward being conditional or 
unconditional on completion of measures to determine 
relative effectiveness and costs for each reward strategy.
Allocation concealment and blinding
All data are self-reports and predominantly input online 
by participants. Where data are collected by post, these 
will be recorded and inputted by the trial manager blind 
to allocation. Data are uploaded directly to an electronic 
database at the CTRC. The system only allows valid values 
to be entered. To prevent any bias in the conduct of the 
study, the chief investigator (FL), trial manager (HR) 
and statistician (SD and PW) will be blinded to treatment 
assignment. Participants, REACT supporters (LC, SF, 
CW), clinical supervisors (SoJ, StJ) and technical staff are 
unblinded.
To minimise unblinding any contact with partici-
pants will be prefaced by a reminder not to disclose trial 
arm. If the trial manager is unblinded, then non-au-
tomated reminders and any data entry will be done by 
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another blind team member. Chief Investigator (FL) 
will be unblinded only in the case of a serious adverse 
event deemed to be study-related to ensure the event is 
appropriately reported and investigated. All instances of 
unblinding will be recorded.
data management storage and security
All participant trial data are collected through an online 
system at CTRC and stored on secure servers physically 
located within access-controlled server rooms and backed 
up nightly to a separate physical location. All identifiable 
data are encrypted using a 256-bit encryption algorithm. 
CTRC servers are subject to penetration testing audits 
undertaken by the University of Liverpool central IT staff. 
Website usage data and qualitative data from the REACT 
group and REACT supporter direct messages are taken 
from the REACT toolkit hosted on a dedicated virtual 
private server at Lancaster University. All communica-
tion with website users is limited to SSL-protected HTTPS 
protocol to protect passwords and data in transit over 
internet.
dATA AnAlySIS
A full statistical analysis plan is available at https:// 
figshare. com/ account/ home#/ projects/ 19975. If 
normally distributed, scores on the primary and 
secondary outcomes will be summarised using means 
and SDs for each arm separately, and will be compared 
between groups using analysis of covariance, adjusting 
for baseline score, and including all participations 
according to the randomisation scheme. If the scores 
are not normally distributed, the median and IQR will 
be presented for each randomised group and will be 
compared using the Mann-Whitney U test. An appro-
priate transformation (eg, log) will be applied, and 
analysis of covariance will be applied to data, adjusting 
for baseline score.
To investigate the relationship between website use 
and outcome, data will be recorded on baseline covari-
ates (correlated with both website use and outcome) and 
relevant website use (from participants in both arms). 
Instrumental variable regression will be implemented to 
estimate impact of website use on the primary outcome 
(GHQ-28 at 24 weeks), as well as to test whether the 
mediator variables actually predict change in outcome. 
Mediating variables will be examined individually in this 
exploratory analysis.
To assess the impact of the second randomisation, the 
number (proportion) of participants providing 24-week 
follow-up data will be presented and compared using the 
χ2 test (or Fisher’s exact test, if expected counts are <5). 
The independent impact of intervention group on reten-
tion rates will be explored by including intervention 
group along with value of the reward (or un/conditional 
nature of the reward) as an explanatory variable in logistic 
regression.
cost-effectiveness
Cost utility with a fully incremental analysis using an NHS 
perspective at 24 weeks will be done. Effectiveness will be 
assessed by changes on GHQ-28. EQ-5D-5L will be used 
to generate QALYs. Uncertainty around cost-effectiveness 
estimates will be explored using cost-effectiveness planes 
(through generating a large number of cost–outcome 
combinations using bootstrapping) and cost-effective-
ness acceptability curves (showing the probability of the 
intervention being cost-effective at various levels of will-
ingness to pay). This allows any uncertainty in the costs 
or outcomes to be reflected in the results presented. 
The NICE Health Technology Assessment (HTA) guid-
ance will be followed. However, costs of informal support 
can impact on cost-effectiveness when it constitutes 
a substantial part of the support provided, so we will 
account for this by also providing results from the wider 
societal perspective including estimates of carers’ produc-
tivity losses.
Missing data analyses
To minimise missing data, participants are required 
to complete the primary outcome measure (GHQ-28) 
before completing any other measures. Participants are 
unable to submit any questionnaire with missing fields, 
thus avoiding missing data within questionnaires. As 
much data as possible will be collected about the reasons 
for missing data, and these will be used to inform the 
handling of missing data. Participants will be invited to 
give reasons for not responding to the email reminders.
The baseline characteristics of those who do/do not 
provide data will be compared to demonstrate whether 
missing data can be assumed to be missing at random (at 
least with respect to recorded baseline characteristics). 
A joint modelling approach (using baseline, 12-week 
and 24-week outcome data) will be used to assess the 
impact of missing data at 24 weeks on the conclusions 
drawn from analysis on primary and secondary efficacy 
outcomes.
Participants are free to withdraw consent from the trial 
at any time without providing a reason, although we invite 
them to tell us why they have withdrawn so that we can 
take this into consideration in future studies.
MonITorIng
The trial is overseen by an independent Data Monitoring 
and Ethics Committee (DMEC) including Professor of 
Trials and Professor of Clinical Psychology, and the TSC 
Chaired by Professor of Clinical Psychology and including 
a trials statistician, trial methodologist and expert relative, 
both funder-appointed (National Institute for Health 
Research (NIHR)). The TSC will oversee trial progress, 
ensure that it is being carried out according to protocol 
and decide on continuation at the end of the internal 
pilot. DMEC will review unblinded data and prioritise 
participant safety, alerting TSC to any concerns regarding 
safety or other ethical issues. TSC will liaise directly with 
 o
n
 22 O
ctober 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-016965 on 18 July 2017. Downloaded from 
10 Lobban F, et al. BMJ Open 2017;7:e016965. doi:10.1136/bmjopen-2017-016965
Open Access 
the trial sponsors (Lancaster University) who may audit 
the trial at any time.
The number (and percentage) of patients with at least 
one major/minor protocol deviation will be summarised 
by treatment group. Eligibility protocol violations and 
multiple registrations per participant or per service user 
will also be reported.
Adverse events
Adverse events are defined as either low risk (clear 
evidence of distress or concerns of risk of harm or abuse 
towards participants or others, but no immediate or 
serious threat of severe harm or risk to life) or high risk 
(clear evidence of immediate risk to life or child welfare). 
Risk can be identified through online questionnaire red 
flag items, posts on the REACT group, direct messages 
to REACT supporters and by the trial manager during 
email or telephone participant contact. Low-risk events 
will be discussed in supervision, documented and trigger 
a standardised email expressing concern and providing 
details of how to seek crisis support. If an immediate 
high risk is identified, either the police (immediate risk 
to life) or social services (risk to child) will be contacted 
as appropriate. Risk will be reported to the supervising 
clinician and documented. The supervising clinician will 
discuss the risk event with the TSC Chair, who will decide 
if the event is related or unrelated to the study. If related, 
Chief Investigator and Trial Manager will be unblinded, 
and the sponsor, ethics committee and funding body will 
be notified. The number of adverse events and how they 
were identified will be recorded for both arms of the trial.
rePorTIng And dISSeMInATIon
The trial will be reported following the Consolidated 
Standards of Reporting Trials guideline.48 The Interna-
tional Committee of Medical Journal Editors guidelines 
on authorship will be followed. Products will be widely 
disseminated through journal articles, conference 
presentations and social media to all relevant stake-
holders internationally, including service users, relatives, 
NHS managers and frontline clinical staff including GPs, 
clinical academics and the general public. A study website 
will provide updates and outputs from the study and links 
to all publications and presentations. Data will be stored 
at Lancaster University and the Trial Management Group, 
which consider applications for access to the data for 
further analyses.
FInAncIAl ArrAngeMenTS
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